Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase-III-Studie zur Bewertung der Sicherheit und Immunogenität einer HIPRA-Kandidaten-Auffrischimpfung gegen COVID-19.

12. November 2026 aktualisiert von: Hipra Scientific, S.L.U

Eine offene, einarmige, multizentrische Phase-III-Studie zur Bewertung der Sicherheit und Immunogenität einer Auffrischimpfung mit einem rekombinanten Protein-RBD-Fusions-Heterodimerkandidaten (PHH-1V) gegen SARS-CoV-2 bei Erwachsenen, die gegen COVID geimpft wurden -19.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

2661

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Milano
      • Milan, Milano, Italien, 20162
        • Hospital de Niguarda
    • BARCELONA
      • Badalona, BARCELONA, Spanien, 08916
        • Hospital Germans Trias I Pujol
      • Barcelona, BARCELONA, Spanien, 08035
        • Hospital Vall Hebron
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08023
        • Hospital HM Delfos
      • Barcelona, Barcelona, Spanien, 08023
        • Hospital Quironsalud Barcelona
      • Mollet del Vallès, Barcelona, Spanien, 08100
        • Hospital de Mollet
    • Girona
      • Girona, Girona, Spanien, 17007
        • Hospital Universitari Dr. Josep Trueta
    • Madrid
      • Madrid, Madrid, Spanien, 28046
        • Hospital Universitario La Paz
      • Madrid, Madrid, Spanien, 28007
        • Hospital Gregorio Marañón
      • Madrid, Madrid, Spanien, 28050
        • Hospital HM Sanchinarro
      • Madrid, Madrid, Spanien, 28660
        • Hospital HM Montepríncipe
      • Madrid, Madrid, Spanien, 28223
        • Hospital Quironsalud Madrid
      • Meco, Madrid, Spanien, 28805
        • Hospital Principe de Asturias
      • Móstoles, Madrid, Spanien, 28938
        • Hospital HM Puerta del Sur
    • Málaga
      • Málaga, Málaga, Spanien, 29010
        • Hospital Regional Universitario de Málaga
    • Spain
      • Barcelona, Spain, Spanien, 17170
        • Hospital Clinic de Barcelona
    • VIZCAYA
      • Barakaldo, VIZCAYA, Spanien, 48903
        • Hospital de Cruces
    • Valencia
      • Valencia, Valencia, Spanien, 46010
        • Hospital Clínico de Valencia

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

16 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male or female, ≥ 16 years old at Day 0.
  • Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
  • Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
  • If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
  • Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
  • Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
  • Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
  • Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
  • Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
  • Male participants must refrain from donating sperm for at least 28 days after day 0.

Exclusion Criteria:

  • History of anaphylaxis to any prior vaccine.
  • Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
  • Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
  • Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
  • Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
  • Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
  • Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
  • Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
  • Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
  • Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
  • Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
  • Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
  • Chronic or recurrent administration of systemic immunosuppressant medication.
  • Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
  • Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
  • Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
  • Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
  • Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental: COVID-19 Vaccine HIPRA 40 ug/dose

COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA

Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Zeitfenster: Day 7

Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.

Day 7
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)
Zeitfenster: Day 28

Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination

Day 28
Incidence of Serious Adverse Events (Safety and tolerability) (SAE)
Zeitfenster: Day 365

Number and percentage of serious adverse events (SAEs) through the end of the study.

Day 365
Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).
Zeitfenster: Day 365

Number and percentage of adverse event of special interest (AESI) through the end of the study.

Day 365
Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)
Zeitfenster: Day 365

Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study.

Day 365
Incidence of Adverse Events in laboratory parameters (Safety and tolerability)
Zeitfenster: Day 365

Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination.

through the end of the study.

Day 365

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in the immunogenicity measured by pseudovirus neutralisation
Zeitfenster: Day 365

Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365.

Day 365
Changes in the immunogenicity measured by pseudovirus neutralisation
Zeitfenster: Day 14

The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14.

Day 14
Changes in the immunogenicity measured by means of total antibody against RBD
Zeitfenster: Day 365

Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365.

Day 365
Changes in the immunogenicity measured by means of total antibody against RBD.
Zeitfenster: Day 14

The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14.

Day 14
Changes in the immunogenicity measured by means of total antibody against RBD
Zeitfenster: Day 14

The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14.

Day 14

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Zeitfenster: Day 365

Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Zeitfenster: Day 365

Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Zeitfenster: Day 365

Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Zeitfenster: Day 365

Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Zeitfenster: Day 365

Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.
Zeitfenster: Day 365

Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

Day 365
To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..
Zeitfenster: Day 14

T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects.

Day 14
To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.
Zeitfenster: Day 14

CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects.

Day 14

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Teresa Prat, HIPRA SICENTIFIC S.L.U

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

3. Februar 2022

Primärer Abschluss (Tatsächlich)

3. März 2023

Studienabschluss (Tatsächlich)

3. März 2023

Studienanmeldedaten

Zuerst eingereicht

8. Februar 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Februar 2022

Zuerst gepostet (Tatsächlich)

18. Februar 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren